Bristol-Myers Squibb gets rated a hold ... so I will wait on the next significant dip and a cooling of the valuation before considering a buy, in addition to a better debt-to-equity picture.

Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...

The move comes less than a year after the company attempted to save $1.5 billion through the layoff of some 2,200 employees.

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

Looking at Bristol-Myers Squibb Company's (NYSE:BMY ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by ...

Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical giant with a market capitalization of $120.8 billion, finds itself at a critical juncture as it navigates a complex landscape of ...

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 150 points on Thursday. The Dow ...

Bristol Myers Squibb (BMY) ended the recent trading session at $56.81, demonstrating a -0.58% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.16%.

Ratings for Bristol-Myers Squibb BMY were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ...

As the major cost-cutting initiative at Bristol Myers Squibb rolls on, the company has launched another round of layoffs in ...

Bristol Myers Squibb believes Alzheimer's treatment is the largest potential market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars ...

David Risinger’s rating is based on the impressive launch performance of Bristol-Myers Squibb’s Cobenfy, which is showing strong sales momentum since its introduction for schizophrenia treatment.